KLK3 and neoplasm: ctDNA% was linked to multiple clinical metrics of tumor burden and disease aggression (Fig. 1B; Fig. 2), although the effect size between ctDNA% and any individual marker (including PSA) was moderate at best (R < 0.55), illustrating that ctDNA% is not merely a surrogate for existing prognostic indices.